Pelvic Infection

CLEVELAND, April 23, 2025 /PRNewswire/ -- Coologics Inc., a clinical-stage medical device company, today announced the successful closing of their Seed round. The round was oversubscribed, demonstrating strong investor confidence in Coologics' vision and technology around its initial product, Vlisse. Continue Reading The seed funding round secured over $3 million in investment, exceeding the initial target of $1.5 million. The funding was led by Prevail and Dream Ventures and saw material participation from two university alumni groups, Ohio State Early Investor Network and Illinois Ventures Illini Angels Program. The Company's CEO/founder, Dr. Kim Langdon and Chief Medical Officer, Dr. Nicole Williams are alumni of the Ohio State University and the University of Illinois, respectively. Coologics raises over $3M in oversubscribed seed round for Vlisse, a novel vaginal infection treatment. Post this This significant capital injection will be instrumental in accelerating Coologics' key milestones, around the completion of their ongoing clinical trial, FDA submission and initial market release of their flagship product, Vlisse. "We are beyond excited about the investor commitment to Coologics," said Dr. Langdon, CEO/Founder. "The overwhelming interest in our seed round validates the critical need for a more effective treatment for vaginal infections. We are thrilled to welcome our new investors and leverage their expertise to accelerate our growth and deliver impactful solutions to female patients and their clinicians." "Dr. Langdon's vision and passion for this problem is what excited us the most about Coologics," said Kerry Lawing, Prevail Ventures CEO, "This market is ripe for innovative solutions like Vlisse. I look forward to watching our experienced teams at Prevail and Dream strategically support Coologics efforts in bringing Vlisse to market." Coologics Inc. is committed to supporting female health and treating the underlying issues affecting women daily. The successful completion of this seed round marks a significant step forward in realizing this vision and bringing its groundbreaking solution, Vlisse, to market. About Coologics Inc. Coologics aims to revolutionize women's health by providing innovative, drug-free solutions for vaginal infections. The company is committed to developing sustainable treatments that reduce the unnecessary use of antibiotics, addressing the growing concern of antibiotic resistance. Vlisse is an innovative, drug-free intravaginal cooling device designed to treat vaginal infections, including VVC, BV, and mixed infections by leveraging its patented cooling mechanism. This approach represents a paradigm shift from traditional antifungal drugs, focusing on restoring the vaginal environment to a healthy state without the use of chemicals. For more information visit Email: [email protected] Media Inquiries contact Rich Mazzola, CFO, 216.376.7972 SOURCE Coologics, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Providers in the United States may now order the FDA-cleared HPV self-collection solution for their patients to use in their offices or other healthcare settings, with goal to reduce barriers to screening by enabling discreet self-collection Quest also plans to make self-collection option available at its 2,000 patient service centers in the United States early next month, expanding access to screening New solution follows company's launch of GTI self-collection option for several STIs and related conditions last fall SECAUCUS, N.J., April 2, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced a new solution aimed at broadening access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. Physicians can now offer patients the option to collect their own specimen for HPV screening in a physician's office or other healthcare setting. The company also plans to introduce the self-collection option for patients, with a physician's order, at its 2,000 Quest patient service centers nationwide early next month. The new option builds on Quest's experience in providing patients with discrete self-collection options. The company introduced a self-collection service option for vaginitis and other genital tract infections, such as chlamydia, gonorrhea, trichomoniasis and Mycoplasma genitalium, at its patient service centers in October 2024, and has experienced strong demand for the solution since the launch. The new offering utilizes the FDA-cleared HPV self-collection solution from Roche (SIX: RO, ROG; OTCQX: RHHBY), approved for use with Roche's cobas® HPV test in May 2024. Interested patients can opt for self-collection in clinical settings, such as a doctor's office, or other healthcare settings. "We are seeing more demand for solutions that empower patients to take an active role in their health care," said Kathleen Valentine, Vice President and General Manager of Women's and Reproductive Health Services at Quest Diagnostics. "Cervical cancer is highly preventable when detected early, and yet, over 4,000 American women will die this year of cervical cancer primarily due to inadequate screening. Our goal is to make HPV screening more accessible and discreet for women who may otherwise skip or delay this vital preventive care test and therefore increase their risk of developing cervical cancer." The solution is not FDA approved for at-home collection, and self-collection is not intended to replace a pelvic examination provided by a clinician. Patients should inform their healthcare provider if they suspect they are pregnant or if they have recently had symptoms of pelvic inflammatory disease (such as pelvic pain, pain with sexual intercourse, unusual vaginal discharge or bad odor). If the patient cannot self-collect a specimen, then collection should be performed in another healthcare setting, like a physician's office, where greater support can be provided. The self-collection option is available at no extra charge for the patient or health plan. Improving access to reduce cervical cancer incidence When testing for HPV in conventional practice, a healthcare provider collects a specimen from a patient in their office or clinic and forwards it to a laboratory for testing. With the new self-collection service, patients may self-collect from their vagina in a private room at a physician's office using a simple step-by-step guide.1 The provider will send the specimen to a nearby Quest Diagnostics testing laboratory. After testing, results will be provided to the physician and patient electronically. The physician may review the results during a separate patient visit and provide further evaluation as needed. "The most reliable cervical cancer method is co-testing, which combines HPV and Pap testing, on a specimen collected by a skilled physician," said board-certified obstetrician and gynecologist Damian P. Alagia, MD, Senior Medical Director, Women's Health, Quest Diagnostics. "Yet, the reality is that some patients, whether due to stigma, trauma or some other factor, are not comfortable undergoing specimen collection by their OBGYN or other doctor. Giving providers and patients options is important for caring for the needs and interests of the individual patient." Historically, ensuring routine cervical cancer screening has been challenging, with 4.4 million fewer American women receiving screenings in 2021 when compared to 2019.2 Incidence of cervical cancer in women aged 30-44 increased 1.7% over the same time.3 Recent draft guidelines from the United States Preventive Services Task Force (USPSTF) on cervical cancer screening states self-collection for HPV screening "has similar accuracy to clinician-collected tests and is associated with increased screening in underscreened individuals and in historically underscreened populations."4 Quest Diagnostics is a leader in women's and reproductive health, which includes a complete menu of solutions for screening for and diagnosing cervical cancer. For more information, visit . About Quest Diagnostics Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in the United States, and our nearly 55,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives and create a healthier world. . SOURCE Quest Diagnostics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

There is currently no FDA-approved vaccine for the prevention of chlamydia infection. Image credit: Shutterstock / Wirestock Creators. The US Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s mRNA vaccine candidate for the prevention of chlamydia infection. The fast track pathway is designed to expedite the development and review of drugs for certain medical conditions where there is currently an unmet need. Pharmaceutical companies are eligible for benefits, including more frequent meetings with the FDA and faster review times. Sanofi’s vaccine is designed to protect against primary genital tract infection and reinfection by the bacterium Chlamydia trachomatis , which is responsible for the most common sexually transmitted bacterial infection in the world. Treatment for the infection currently includes a regimen of antibiotics, although there are no pharmacological options to prevent the disease. Sanofi stated that health programmes initiated to prevent infection rates from rising have proven insufficient, highlighting the public health need for a vaccine. The consequences of infection in women are more serious than in men, given that pelvic inflammatory diseases can arise, a complication that can lead to infertility. Sanofi is developing the vaccine in partnership with the Queensland government, Griffith University, and the University of Queensland, all based in Australia . The vaccine has produced a “promising pre-clinical programme”, according to the drugmaker. A Phase I/II randomised clinical study, which is slated to start in the coming days, will evaluate the immunogenicity and safety of the candidate in adults aged 18 to 29 years. Sanofi has remained tight-lipped on further details of the vaccine, saying only that it is mRNA-based. Sanofi has various mRNA vaccines in development for infectious diseases, including respiratory syncytial virus (RSV), influenza, and meningitis, among others. Sanofi’s global head of vaccine research and development Jean-François Toussaint said: “Millions of people currently live with undiagnosed chlamydia, including asymptomatic infection that can also cause severe long-term health effects if left untreated. “Antibiotics to treat chlamydia have not been successful in controlling rising infection rates. With our programme, we aim to make chlamydia a preventable disease through vaccination.” A separate vaccine candidate has already demonstrated positive results in a randomised Phase I trial (NCT03926728). Funded by the EU Horizon programme, researchers from the UK and Denmark reported in The Lancet Infectious Diseases that their candidate was safe and induced an immune response in adults. The research team have earmarked a larger Phase II trial. There are already a handful of vaccines approved to prevent certain sexually transmitted infections, including HPV and hepatitis B. mRNA vaccine coverage on Pharmaceutical Technology (or Clinical Trials Arena) is supported by Trilink . Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper Enhance your mRNA production with market leading capping Optimising mRNA production raises myriad questions for biomanufactures around how to navigate costs and maximise efficiency. TriLink BioTechnologies has leveraged its expertise to provide answers. Their CleanCap® M6 analog improves mRNA yields and boosts protein expression. With its newly optimised pulse-feed protocol, manufacturers can double production at just a fraction of the cost. As a proven solution in scalable IVT reactions, CleanCap® M6 ensures consistent quality and reduced costs for mRNA production. Download now to learn more. Thank you. You will receive an email shortly. Please check your inbox to download the Whitepaper. By Trilink Thematic By downloading this Whitepaper, you acknowledge that GlobalData may share your information with Trilink Thematic and that your personal data will be used as described in their Privacy Policy